YPYara A. Park

Yara A. Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yara A. Park has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    When Strong Recommendations Rest on Weak Evidence: Lessons From Therapeutic Apheresis Guidelines

    by Jeremy W. Jacobs, Garrett S. Booth, Brian D. Adkins, Victoria Costa, Sheharyar Raza, Yara A. Park, Joseph Yossi Schwartz, Evan M. Bloch

    The American Society for Apheresis (ASFA) guidelines serve as a global standard for therapeutic apheresis practice. However, our analysis of the 2023 guidelines reveals discordance between the strength of recommendation and the quality of evidence. Among 166 indications, one‐third carry strong recommendations, yet only 8% are supported by high‐quality evidence. Over half (55%) are informed by low‐ or very‐low quality evidence. This mismatch is most pronounced for Category I indications, where apheresis is considered first‐line therapy: nearly one‐third are based on low‐quality data, yet 89% receive strong recommendations. Weak evidence is nine times more likely to prompt a strong recommendation for Category I versus Category III indications. This misalignment risks overutilization of apheresis, introduces ethical hurdles for clinical trials by diminishing equipoise, and may mislead patient expectations during informed consent. We advocate for greater transparency by stating the rationale underlying strong recommendations despite low‐quality evidence, acknowledgment of uncertainty where applicable, and suggested research to strengthen the evidence.


  • The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center

    by Ashley J. Crosby, Mariama Evans, Danielle L. V. Maracaja, Yara A. Park, James F. Howard, Matthew S. Karafin

    Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies against proteins of the neuromuscular junction, such as the acetylcholine receptor (AChR). While therapeutic plasma exchange (TPE) has been a standard chronic therapy for patients with poorly controlled MG, new medications have recently been approved by the FDA for such patients. We report the impact of a new therapy, efgartigimod, on the number of therapeutic plasma exchanges performed on patients with generalized MG in our apheresis unit. A retrospective chart review was performed for patients with MG between 2018–2019 (pre‐efgartigimod) and 2022–2023 (post‐efgartigimod). We evaluated any changes between the two periods, including the total number of MG patients, the proportion of TPEs that were performed for MG, and the proportion of inpatient TPEs for MG. A statistically significant reduction (p < 0.0001) was observed in the proportion of total TPE procedures for MG between the two time periods. In AChR‐antibody positive (AChR‐Ab +) patients who received both inpatient and outpatient procedures, there was a significant increase in the proportion of inpatient procedures post‐efgartigimod (p = 0.0035). Our study demonstrated a decrease in the overall use of chronic TPE for MG over the 2‐year period following the release of efgartigimod. However, there will remain a role for TPE in the setting of acute MG flares, the inpatient setting, during pregnancy, and in those who do not tolerate the new medications.


  • Use of a novel configuration of ports for patients needing intermittent long‐term apheresis

    by Matthew S. Howlett, Kimani Hicks, Yara Park, Matthew S. Karafin, Peter R. Bream

    Purpose: In patients with a need for frequent but intermittent apheresis, vascular access can prove challenging. We describe the migration of the use of a Vortex LP dual lumen port (Angiodynamics, Latham, NY) to one Powerflow and one ClearVUE power injectable port (Becton Dickinson, Franklin Lakes, NJ) in a series of patients undergoing intermittent apheresis.Materials and Methods: All patients had a need for long‐term intermittent apheresis. Eight had double lumen Vortex port (pre) and were exchanged for one Powerflow port and one conventional subcutaneous venous port with 90° needle entry (post) while 12 did not have any port in place and received the same configuration. IRB approval was granted. We recorded the treatment time, flow rate, and tissue plasminogen activator (tPA) use for five treatment sessions after placement. When available, we compared five treatments with the Vortex port and the new configuration.Results: The mean treatment time is reduced with the new configuration (P = 0.0033). The predicted mean treatment time, adjusting for gender, race, BMI and age and accounting for correlations within a patient is 91.18 min pre and 77.96 min post. The flow rate is higher with the new configuration (P < 0.0001). The predicted mean flow rate in mL/min is 61.59 for the Vortex port and 71.89 for the new configuration. tPA use was eliminated in the population converted from Vortex ports and had a 48% reduction when compared to all other configurations in the study.Conclusion: The introduction of a novel device configuration of venous access ports for intermittent apheresis resulted in higher flow rates and less total time for treatment. Use of tPA was greatly reduced. These results suggest that the new configuration could result in less expense for the hospital and better throughput in a busy pheresis practice.Clinical trial registration with ClinicalTrials.gov: NCT04846374.


  • How do I reduce variation in red blood cell transfusion practices in a large integrated health care system?

    by Pamela Entzel, Matthew Nielsen, Susan Weiss, Yara A. Park, Rommel Lu, Jacquelyn Baskin‐Miller, Blake Hutchinson, Prestige Obioma, Xinming An, Greg Balfanz

    Background: Reducing variation in transfusion practices can prevent unwarranted transfusions, an outcome that improves quality of care and patient safety, while lowering costs and eliminating waste of blood. We developed and assessed a system‐wide initiative to reduce variation in red blood cell (RBC) transfusion in terms of both transfusion utilization and the number of units transfused.Intervention Design And Methods: Our initiative combined a single‐unit default order for RBC transfusion in hemodynamically stable, non‐bleeding patients with a “Why Give 2 When 1 Will Do?” Choosing Wisely campaign, while also promoting a restrictive hemoglobin threshold (Hb p < .001). The greatest change in ordering practices was at community hospitals, where single‐unit orders increased from 46% to 65% (p < .001). Over the same time period, the system‐wide mean (SD) Hb result prior to transfusion fell from 7.3 (0.05) to 7.2 g/dl (0.04) (p < .05). We estimate this effort saved over 4000 units of blood and over $4 million in direct and indirect costs in its first year.Discussion: By combining a single‐unit default setting in the RBC order with a restrictive hemoglobin threshold, we significantly reduced variation in ordering practices. This effort demonstrates the value of single‐unit policies and “nudges” in system‐wide patient blood management initiatives.


  • ASFA's Response to 'Gender Inequities in Transfusion Medicine Society Recognition Awards'

    by Betty Doggett, Nicole A Aqui, Yvette M Miller, Yara A. Park, Jennifer Schneiderman, Michael Linenberger


  • Blood conservation strategies at United States hospitals during the COVID‐19 pandemic: Findings from a multi‐institutional analysis ‐ International Society of Blood Transfusion survey

    by Jeremy W. Jacobs, Matthew S. Karafin, Elizabeth S. Allen, Elizabeth Abels, Yara A. Park, Laura D. Stephens, Dawn C. Ward, Jennifer S. Woo, Eric A. Gehrie, Garrett S. Booth, et al.

    Background: Due to the coronavirus disease 2019 (COVID‐19) pandemic, the transfusion medicine community has experienced unprecedented blood supply shortages since March 2020. As such, numerous changes to everyday practice have occurred with a specific emphasis on blood conservation. We sought to determine the strategies used to mitigate blood shortages and promote blood conservation during the pandemic.Methods: An anonymous, 37‐question survey was developed using Research Electronic Data Capture and distributed via e‐mail to transfusion medicine specialists across the US obtained via publicly available databases.Results: Amongst surveyed [41.1% response rate (51/124 institutions)], 98.0% experienced a product shortage, with the greatest number reporting red blood cell (RBC) shortages (92.0%). This led to 35.3% of institutions altering the composition and/or number of blood product suppliers, including a 100% increase in the number of institutions acquiring blood from organizations that connect hospital transfusion services with blood collection centers (e.g., Blood Buy) compared to before March 2020. Prospective triaging of blood products was the most common blood conservation strategy (68.1%), though 35.4% altered their RBC exchange or transfusion program for patients receiving chronic RBC transfusion/exchange. As a result of these changes, 78.6% of institutions reported that these changes resulted in a reduction in blood product usage, and 38.1% reported a decrease in product wastage.Conclusions: Most hospitals experienced the effects of the supply shortage, and many of them implemented blood conserving measures. Conservation strategies were associated with decreased blood utilization and waste, and future studies could evaluate whether these changes persist.


  • Considerations for immune effector cell therapy collections: a white paper from the American Society for Apheresis

    by Hien D. Liu, Leon Su, Jeffrey L. Winters, Suzanne R. Thibodeaux, Yara A. Park, YanYun Wu, Joseph Schwartz, Abba C. Zubair, Jennifer Schneiderman, Gaurav K. Gupta, et al.


  • Evaluation of mobilization efficacy with an extended interval following plerixafor administration

    by Sarah E Stump, Morgan Trepte, J Ryan Shaw, Tatjana Grgic, Jonathan R Ptachcinski, Andrew Sharf, Marcie Riches, Thomas C Shea, Yara A Park, Maurice D Alexander

    Plerixafor is a hematopoietic stem cell mobilizing agent used in combination with granulocyte-colony stimulating factor to improve collection for autologous stem cell transplantation. Despite a recommendation for administration 11 h prior to apheresis per package labeling, logistical challenges lead many institutions to administer plerixafor at an extended interval. The purpose of this study was to determine if plerixafor effectively and efficiently mobilizes CD34+ cells when given at an extended interval prior to apheresis. This was a retrospective evaluation of adult patients who received plerixafor based on an algorithm reserving daily plerixafor only for patients with a pre-apheresis CD34+ count of < 20 cells/µL (pre-apheresis plerixafor) or with a low CD34+ yield after the first apheresis session (rescue plerixafor). The primary outcome was achievement of a disease-specific collection goal of ≥ 6 ×106 CD34+ cells/kg for multiple myeloma and ≥ 4 ×106 CD34+ cells/kg for lymphoma. The mean interval between plerixafor administration and apheresis was 17 h in this study. Despite this extended interval, 64% of patients met their disease-specific collection goal. A minimum collection goal of ≥ 2 ×106 CD34+ cells/kg was achieved by 95% of patients. Mobilization remained efficient with a median of two days to complete collection. Based on this data, plerixafor effectively and efficiently mobilizes CD34+ cells when given at an extended interval prior to apheresis.